S&P 500 Futures
(0.13%) 5 334.25 points

Dow Jones Futures
(0.04%) 40 152 points

Nasdaq Futures
(0.20%) 18 673 points

Oil
(-0.25%) $79.86

Gas
(1.14%) $2.66

Gold
(0.91%) $2 439.50

Silver
(2.35%) $32.00

Platinum
(-0.26%) $1 087.20

USD/EUR
(0.07%) $0.920

USD/NOK
(0.01%) $10.68

USD/GBP
(0.07%) $0.788

USD/RUB
(-0.46%) $90.56

Realtime updates for Praxis Precision [PRAX]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

BUY

100.00%
return 8.49%

SELL

33.33%
return 12.44%

Last Updated17 May 2024 @ 16:00

25% discount on Stockinvest.us - Use code: Podcast

0.40% $ 45.39

BUY 137782 min ago

@ $42.09

Issued: 14 Feb 2024 @ 14:09

Return: 7.84%

Previous signal: Feb 14 - 10:24

Previous signal: Sell

Return: -4.89 %

Live Chart Being Loaded With Signals

Commentary (17 May 2024 @ 16:00):

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance...

Stats
Today's Volume	273 439
Average Volume	236 940
Market Cap	776.53M
EPS	$0 ( 2024-05-13 )
Next earnings date	( $0 ) 2024-08-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.43
ATR14	$0.183 (0.40%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-12	Mastrocola Lauren	Sell	48	Common Stock
2024-02-12	Nemiroff Alex	Sell	51	Common Stock
2024-02-12	Souza Marcio	Sell	271	Common Stock
2024-01-12	Kelly Timothy Edwin	Buy	30 000	Stock Option (Right to Buy)
2024-01-12	Souza Marcio	Buy	100 000	Stock Option (Right to Buy)

INSIDER POWER
98.07
Last 99 transactions
Buy: 3 195 196 \| Sell: 875 304

Volume Correlation

Long: -0.07 (neutral)

Short: 0.56 (weak)

Signal:(55.519) Neutral

Praxis Precision Correlation

10 Most Positive Correlations
KROS	0.889
LPLA	0.874
AIHS	0.87
XOMA	0.868
HQY	0.867
ARQT	0.857
ELEV	0.855
KBWP	0.852
LVO	0.849
EWJV	0.847

10 Most Negative Correlations
DERM	-0.913
PODD	-0.898
FLNC	-0.895
MSEX	-0.893
ACON	-0.887
UPST	-0.885
FFIE	-0.881
MTLS	-0.879
AUR	-0.879
GH	-0.877

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Praxis Precision Correlation - Currency/Commodity

0.16
( neutral )

0.03
( neutral )

0.20
( neutral )

0.28
( neutral )

-0.39
( neutral )

-0.05
( neutral )

Praxis Precision Financials

Annual	2023
Revenue:	$2.45M
Gross Profit:	$2.02M (82.35 %)
EPS:	$-18.69

FY	2023
Revenue:	$2.45M
Gross Profit:	$2.02M (82.35 %)
EPS:	$-18.69

FY	2022
Revenue:	$0
Gross Profit:	$-1.17M (0.00 %)
EPS:	$-69.33

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-3.74

Financial Reports:

No articles found.

Praxis Precision Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Praxis Precision

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators

Investing in the stock market involves risk and the value of your investment can fluctuate. The stock market can be affected by a variety of factors, including economic conditions, company performance, and global events. There is no guarantee of profit and you could lose money. Please consider your financial situation, investment goals, and level of risk tolerance before making any investment decisions. Consult with a financial advisor for personalized advice.